AMN Healthcare Services heads into its August 6 earnings report with shorts rebuilding, options traders hedging heavily, and a fresh analyst upgrade that the market has not fully priced in.
The most striking signal this week is in options. Defensive positioning has reached near-extreme levels — the put/call ratio hit 1.96 on Tuesday, almost touching its 52-week high of 1.99 on Monday. That reading is more than two standard deviations above the 20-day mean of 1.40, the kind of spread that points to systematic demand for downside protection rather than routine hedging. The shift is sharp and recent: as late as mid-June, the PCR was running below 0.85, a broadly constructive reading. In six weeks, options traders have swung from cautiously bullish to decisively defensive.
Short interest reinforces that caution. Shorts have rebuilt steadily through July, with the SI % of free float rising to 9.2%, up 8.3% on the week and 18.3% on the month. That puts the short position at a level that warrants attention: nine out of every hundred shares in the free float is currently borrowed and sold. The borrow market itself remains relaxed — cost to borrow is just under 0.5%, essentially negligible, and availability is ample at 528%, meaning there is no friction stopping further short accumulation if sentiment sours further. That said, the ORTEX short score of 52.1 is only modestly above neutral and has moved up gradually rather than in a rush, suggesting rebuilding rather than a conviction short attack.
The analyst picture offers a counterweight. Truist Securities raised its target from $26 to $40 this morning while maintaining its Buy rating — a bold move that re-anchors the upside case well above current levels. That lift comes after the stock's May earnings print delivered a 38% single-day gain and a 44% five-day move, the kind of reaction that can prompt analysts to rethink their models. The consensus mean target sits at $31.86, fractionally below the current price of $34.20, but the Truist move implies the distribution of targets is widening. Bulls point to strong Q1 outperformance, double-digit EBITDA growth expectations, and the company's diversified workforce solutions platform. Bears flag visa retrogression headwinds on the international book, secular pressure on VMS revenue, and the concentration risk from Kaiser Permanente accounting for roughly a third of revenues.
Valuation multiples have drifted higher with the price — the P/E has expanded 3.3 points over the past month to 19.1x, and EV/EBITDA has moved up 0.4 turns to 9.0x. Neither reading looks stretched for a company with improving earnings momentum, though the 30-day EPS momentum factor score of 8 (out of 100) flags that near-term estimate revisions have been running weak even as the longer-term earnings trajectory has recovered. The stock's 10.4% gain over the past month and 5.2% rise this week leave it sitting above most analysts' targets, which creates a delicate setup: the price has moved, but the Street has not unanimously followed.
The earnings history adds to the complexity. The May print produced the kind of single-day move — 38% up — that can reset an entire narrative, and it was followed by a further 44% gain over the subsequent week. That reaction cleared years of underperformance and explains both the short rebuilding (new shorts entering after the spike) and the defensive options skew (existing holders protecting gains ahead of the next event). The August 6 release will be the first test of whether that May beat was structural recovery or a one-off reset. What to watch: whether the PCR holds near its highs into the event date, and whether short interest continues its current trajectory toward 10% of the float — two metrics that together would indicate a genuinely charged setup going into the print.
See the live data behind this article on ORTEX.
Open AMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
